Company working on a number of agreements in parallel to ensure broad and equitable supply of the vaccine throughout the world at no profit during the pandemic. First agreements to supply at least 400 million doses; Company has total capacity sourced for one billion doses through 2020 and into 2021; continues to increase capacity further. More than $1bn US BARDA investment to support development and production of the vaccine.
Gedeon Richter Plc. ("Richter") today announced that it has entered into an asset purchase agreement with Mycenax Biotech Inc. ("Mycenax") in respect of biosimilar tocilizumab ("Product") for the treatment of rheumatoid arthritis.
The Gedeon Richter Plc. hereby informs its honourable shareholders that ZAO Firma CV «PROTEK» has submitted a voluntary purchase offer to the holders of PAO «PROTEK» common shares, to buy back the shares issued by PAO «PROTEK» at a purchase price of RUB 100 (one hundred) per share.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of molecular diagnostics and sample preparation technologies, today announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher's proposal to acquire QIAGEN for €39 per share in cash. The offer price represents a premium of approximately 23% to the closing price of QIAGEN's common stock on the Frankfurt Prime Standard on March 2, 2020, the last trading day prior to the announcement of the transaction. Thermo Fisher will commence a tender offer to acquire all of the ordinary shares of QIAGEN.
The NCI awarded a 5-year, $8.3 million research grant to Weill Cornell Medicine, Moffitt Cancer Center and Universidade de Sao Paulo in Brazil to investigate strategies to prevent HPV-related cancers among individuals with HIV.
BioNTech (Nasdaq: BNTX, “BioNTech”) and Neon Therapeutics, Inc. (Nasdaq: NTGN, “Neon”) today announced that they have entered into a definitive merger agreement under which BioNTech will acquire Neon in an all-stock transaction valued at approximately $67.0 million.
Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy Xyphos shareholders to receive up to $665 million in structured, milestone-based acquisition